Cementless Endoprosthesis in the Treatment of Giant Cell Tumor of the Tibia: Eighteen Years of Evolution

Mello, Glauco Pauka; Sonehara, Helio Ayabe; Neto, Mário Armani

doi:10.1016/s2255-4971(15)30312-8

Cited by 2 publications

(4 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5 , 6 Complete bone resection can also be performed in some cases without marked functional impairment, such as in the ulna, fibula, and small bones of the hand and foot. 1 , 2 , 9 …”

Section: Discussionmentioning

confidence: 99%

“…It consists of giant osteoclast-like cells interspersed with a hypercellular and vascularized stroma, which differentiates it from other tumor or pseudotumoral lesions, such as chondroblastoma, brown tumor of hyperparathyroidism, and aneurysmal bone cyst. 2 …”

Section: Introductionmentioning

confidence: 99%

“…in an attempt to decrease the chance of recurrence. 2 Campanacci III tumors, due to their size and local aggressiveness, are usually best addressed through wide resection with defect correction. 1 , 6…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Giant cell tumor locally advanced around the knee: treatment and literature review

Rigollino

Fernando

Tanaka

et al. 2017

Revista Brasileira de Ortopedia (English Edition)

View full text Add to dashboard Cite

Giant cell tumor (GCT) is a benign bone tumor with aggressive characteristics. They are more prevalent in the third decade of life and demonstrate a preference for locating in the epiphyseal region of long bones. They have a high local recurrence rate, which depends on the type of treatment and initial tumor presentation. The risk of lung metastases is around 3%.Between October 2010 and August 2014, nine patients diagnosed with locally advanced GCT or with pathological fracture to the knee level underwent surgical treatment. The aim of this study was to evaluate the results of the treatment, particularly with regard to relapse, and to conduct a literature review.There was a predominance of males (77.7%). The most common location was the distal femur. Four patients (44%) developed local recurrence in the first year after surgery, three in distal femur and one in proximal tibia. Of the two patients with pathologic fracture at diagnosis, one of them presented recurrence after five months.The treatment of GCT is still a challenge. The authors believe that the best treatment method is wide resection and reconstruction of bone defects with non-conventional endoprostheses. Patients should be aware and well informed about the possible complications and functional losses that may occur as a result of the surgical treatment chosen and the need for further surgery in the medium and long term.

show abstract

“…5 , 6 Complete bone resection can also be performed in some cases without marked functional impairment, such as in the ulna, fibula, and small bones of the hand and foot. 1 , 2 , 9 …”

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Giant cell tumor locally advanced around the knee: treatment and literature review

Rigollino

Fernando

Tanaka

et al. 2017

Revista Brasileira de Ortopedia (English Edition)

View full text Add to dashboard Cite

show abstract

“…GCTB mainly occurs in skeletally mature patients, with a peak incidence between ages 20 and 45 years and slight predominance among females. [1][2][3] GCTB commonly arises at the epiphyses of long bones, like the distal femur, proximal tibia, distal radius and proximal humerus. 4 In addition, it is often found close to joints, and therefore causes movement limitation, joint effusion and synovitis.…”

Section: Introductionmentioning

confidence: 99%

Can p63 serve as a biomarker for diagnosing giant cell tumor of bone? A systematic review and meta-analysis

et al. 2020

View full text Add to dashboard Cite

BACKGROUND: Tumor protein p63 (p63) has been reported to be highly expressed in giant cell tumor of bone (GCTB). Whether p63 can be treated as a diagnostic marker for GCTB remains unclear. OBJECTIVE: We conducted a meta-analysis to evaluate the applicability of p63 in diagnosing GCTB. DESIGN AND SETTING: Systematic review and meta-analysis carried out in a public hospital, Hong Kong, China. METHODS: We searched PubMed, EMBASE and the Cochrane Library from inception to April 30, 2019. Literature in English or Chinese about the differential diagnosis of GCTB using p63 were included. Animal experiments, reviews, correspondence, case reports, expert opinions and editorials were excluded. Studies were also excluded if they did not provide sufficient information to construct a 2 × 2 contingency table. We calculated individual and pooled sensitivities and specificities. We used I² as an indicator of heterogeneity. RESULTS: Out of 88 records identified, 8 articles on 788 GCTB patients fulfilled the inclusion criteria and were included in the present analysis. Bivariate analyses yielded a pooled mean sensitivity of 0.87 (95% confidence interval, CI, 0.72-0.95) and specificity of 0.71 (95% CI, 0.56-0.82) for using p63 as a biomarker in diagnosing GCTB. The area under the receiver operating characteristic curve was 0.86 (95% CI, 0.82-0.88). CONCLUSION: p63 is a helpful indicator in diagnosing GCTB due to its high sensitivity and specificity. Nonetheless, the results need to be carefully interpreted based on other diagnostic methods such as imaging. SYSTEMATIC REVIEW REGISTRATION: 164115 (PROSPERO registration number)

show abstract

Cementless Endoprosthesis in the Treatment of Giant Cell Tumor of the Tibia: Eighteen Years of Evolution

Cited by 2 publications

References 15 publications

Giant cell tumor locally advanced around the knee: treatment and literature review

Giant cell tumor locally advanced around the knee: treatment and literature review

Can p63 serve as a biomarker for diagnosing giant cell tumor of bone? A systematic review and meta-analysis

Contact Info

Product

Resources

About